Vikman S, Airaksinen K E J, Tierala I, Peuhkurinen K, Majamaa-Voltti K, Niemelä M, Tuunanen H, Nieminen M S, Niemelä K
Heart Center, Tampere University Hospital, PL 2000, 33521 Tampere, Finland.
J Intern Med. 2004 Oct;256(4):316-23. doi: 10.1111/j.1365-2796.2004.01374.x.
Treatment options for acute coronary syndrome (ACS) without ST elevation have evolved rapidly during the recent years, but the successful implementation of practice guidelines incorporating new treatments into practice has been challenging. In this study, we evaluate whether targeted educational intervention could improve adherence to treatment guidelines of ACS without ST elevation.
DESIGN, SETTING AND SUBJECTS: A previous study, FINACS I, evaluated the treatment and outcome of 501 consecutive non-ST elevation ACS patients that were referred in early 2001 to nine hospitals, covering nearly half of the Finnish population. That study revealed poor adherence to ESC guidelines, so targeted educational intervention on optimal practice was arranged before the second study (FINACS II), which was performed in the same hospitals using the same protocol as FINACS I. FINACS II, undertaken in early 2003, evaluated 540 consecutive patients. Interventions. Targeted educational programmes on optimal practice.
The use of evidence-based therapies in non-ST elevation ACS patients. In-hospital event-free (death, new myocardial infarction, refractory angina, readmission with unstable angina and transient cerebral ischaemia/stroke) survival, and event-free survival at 6 months.
Baseline characteristics and risk markers were similar in both studies, and no significant changes in resources were seen. In 2003, the in-hospital use of statins, ACE-inhibitors, clopidogrel and glycoprotein (GP) IIb/IIIa receptor antagonists increased significantly, and in-hospital angiography was performed more often, especially in high-risk patients (59% vs. 45%, P < 0.05); waiting time also shortened (4.2 +/- 5.5 vs. 5.8 +/- 4.7 days, P < 0.01). Overall no significant change was seen in the frequency of death either in-hospital (2% vs. 4%, P = NS) or at 6 months (7% vs. 10%, P = NS) in FINACS II. However, the survival of high-risk patients improved both in-hospital (95% vs. 90%, P = 0.05) and at 6 months (89% vs. 78%, P = 0.05).
In patients with non-ST elevation ACS-targeted educational interventions appeared to be associated with improved adherence to practical guidelines, which yielded a better outcome in high-risk ACS patients.
近年来,非ST段抬高型急性冠状动脉综合征(ACS)的治疗选择迅速发展,但将新治疗方法纳入实践的实践指南的成功实施一直具有挑战性。在本研究中,我们评估了针对性的教育干预是否能提高对非ST段抬高型ACS治疗指南的依从性。
设计、设置和研究对象:之前的一项研究FINACS I评估了2001年初转诊至9家医院的501例连续非ST段抬高型ACS患者的治疗情况和结局,这些医院覆盖了近一半的芬兰人口。该研究显示对欧洲心脏病学会(ESC)指南的依从性较差,因此在第二项研究(FINACS II)之前安排了关于最佳实践的针对性教育干预,第二项研究于2003年初在相同的医院采用与FINACS I相同的方案进行。FINACS II评估了540例连续患者。干预措施为关于最佳实践的针对性教育项目。
非ST段抬高型ACS患者使用循证疗法的情况。住院期间无事件(死亡、新发心肌梗死、难治性心绞痛、因不稳定型心绞痛再次入院以及短暂性脑缺血/中风)生存率,以及6个月时的无事件生存率。
两项研究的基线特征和风险标志物相似,且未观察到资源有显著变化。2003年,他汀类药物、血管紧张素转换酶(ACE)抑制剂、氯吡格雷和糖蛋白(GP)IIb/IIIa受体拮抗剂的院内使用显著增加,并且更频繁地进行了院内血管造影,尤其是在高危患者中(59%对45%,P<0.05);等待时间也缩短了(4.2±5.5天对5.8±4.7天,P<0.01)。总体而言,FINACS II中住院期间(2%对4%,P=无显著性差异)或6个月时(7%对10%,P=无显著性差异)的死亡频率均未观察到显著变化。然而,高危患者的生存率在住院期间(95%对90%,P=0.05)和6个月时(89%对78%,P=0.05)均有所提高。
在非ST段抬高型ACS患者中,针对性的教育干预似乎与提高对实践指南的依从性相关,这在高危ACS患者中产生了更好的结局。